BD (NYSE: BDX) today set the record date for the planned spin-off of its Biosciences & Diagnostics business to Waters ...

With Waters stockholders voting to issue shares, the companies are targeting a Feb. 9 close date for the deal.

Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters' proven execution model Doubles Waters' total addressable market to ...

BD (Becton, Dickinson and Company) (NYSE: BDX) ("BD" or the "Company") today announced that the Company's Board of Directors has set the close of business on February 5, 2026, as the record date for ...

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics, which aims to make taking a high-quality sample in pharmacies, grocery stores or at home as easy as ...

Compelling opportunity expected to unlock substantial value through enhanced focus, tailored investment and capital allocation, and optimized market valuation "New BD," built on momentum of BD 2025 ...

BD (Becton, Dickinson and Co.) announced Aug. 15 a commercial collaboration under which the Franklin Lakes-based company will offer Accelerate Diagnostics Inc.’s rapid tests through its global sales ...

BD Diagnostics, a segment of Becton, Dickinson and Co., has announced it received FDA clearance to market a new MRSA test, according to a news release. BD received clearance for the BD MAX MRSA ...

In collaboration with customers and recycling partners, Envetec is developing sustainable circular pathways for treated ...

New capillary blood collection device combined with innovative sample handling and analytical technologies in clinical studies aim to make diagnostic blood testing more accessible and convenient ...

BD Diagnostics, a part of global medical technology company BD (Becton, Dickinson and Company), and Biodiversity SpA, a biotechnology company for molecular diagnostics, announced a regional ...